文献速递消化道肿瘤放疗放疗物理与技术

碳离子放疗治疗非转移性胰腺癌:前瞻性2期PACK研究最终结果

Carbon ion radiotherapy for non-metastatic pancreatic cancer: final results of the prospective phase 2 PACK-study (NCT04194268).
PubMed 文献 · Radiother Oncol · 2026-10-22

这项单中心前瞻性2期研究纳入25例局部晚期或局部复发不可手术的非转移性胰腺癌患者,采用碳离子放疗48 Gy(RBE)分12次联合每周吉西他滨300 mg/m2化疗。

要点

  • 碳离子放化疗在非转移性胰腺癌中显示出令人鼓舞的总生存和可接受的毒性。
  • 1年和2年总生存率分别为78%和59%,中位总生存26.5个月。
  • 仅3例治疗相关3级毒性,无4-5级毒性。

核心结论

  • 碳离子放化疗在非转移性胰腺癌患者中显示出令人鼓舞的总生存和可接受的毒性。
  • 建议后续开展随机3期试验比较碳离子放疗与传统放化疗或化疗的总生存优效性。

研究设计与样本

  • 单中心研究者发起的2期试验,纳入25例局部晚期或局部复发胰腺癌患者。
  • 碳离子放疗采用强度控制光栅扫描系统,总剂量48 Gy(RBE),分12次。
  • 同步每周吉西他滨300 mg/m2化疗。
  • 主要终点为1年总生存率,定义为自研究入组起算的时间。

主要发现

  • 1年和2年总生存率分别为78%[CI 63%;97%]和59%[CI 41%;84%]。
  • 中位总生存为26.5个月。
  • 1年和2年无进展生存率分别为26%[CI 13%;52%]和10%[CI 3%;37%],中位无进展生存8.1个月。
  • 治疗相关CTCAE 3级毒性3例,包括腹痛1例、上消化道出血1例和输尿管狭窄1例。
  • 未观察到治疗相关CTCAE 4-5级毒性。

关键数值与推荐

  • 碳离子放疗总剂量48 Gy(RBE),分12次。
  • 同步吉西他滨300 mg/m2每周。
  • 毒性评价采用CTCAEv5.0。

临床怎么用

  • 碳离子放化疗可作为非转移性不可手术胰腺癌的一种治疗选择,需关注3级毒性。
  • 该方案尚需随机3期试验验证其总生存优效性后方可改变临床实践。

局限性

  • 缺乏与传统放化疗或化疗的随机对照比较。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To evaluate the efficacy and safety of carbon ion radiotherapy (CIRT) in patients with non-metastatic, inoperable pancreatic cancer in a prospective phase 2 setting. METHODS: In this single-center investigator-initiated phase 2 trial, 25 patients with locally advanced or locally recurrent pancreatic cancer were included. CIRT was performed using an intensity-controlled rasterscanning system for beam application [total dose: 48 Gy (RBE), 12 fractions]. Concurrent chemotherapy with Gemcitabine 300 mg/m2 was administered weekly. The primary endpoint was the 1-year OS rate, defined as time from study inclusion. 1y- and 2y-OS and -PFS were calculated using the Kaplan-Meier method, 95 % confidence intervals are shown. Toxicity was evaluated using CTCAEv5.0. RESULTS: Twenty-three patients were included in the final analysis. After the completed 12-month follow-up of the last patient, the 1- and 2-year OS rates were 78 % [CI 63 %; 97 %] and 59 % [CI 41 %; 84 %]. The median OS was 26.5 months. The 1- and 2-year PFS rates were 26 % [CI 13 %; 52 %] and 10 % [CI 3 %; 37 %] with a median PFS of 8.1 months. Study treatment was well tolerated with three treatment-related CTCAE grade 3 toxicities, including one case of abdominal pain, one upper gastrointestinal hemorrhage and one ureteric stricture. No treatment-related CTCAE grade 4-5 toxicities were observed. CONCLUSION: Chemoradiation with carbon ions demonstrated encouraging overall survival and acceptable toxicity in non-metastatic pancreatic cancer patients. A subsequent randomized Phase 3 trial should investigate OS superiority of CIRT compared to conventional chemoradiotherapy or chemotherapy.

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. Liermann J, Naumann P, Jäkel C, et al. Carbon ion radiotherapy for non-metastatic pancreatic cancer: final results of the prospective phase 2 PACK-study (NCT04194268). Radiother Oncol. 2026. PMID: 42913944. doi:10.1016/j.radonc.2026.111836

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。